NASDAQ:VCEL Vericel (VCEL) Stock Price, News & Analysis $52.32 +0.62 (+1.20%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$51.39▼$52.9050-Day Range$41.71▼$52.9052-Week Range$30.18▼$54.08Volume252,448 shsAverage Volume465,599 shsMarket Capitalization$2.54 billionP/E RatioN/ADividend YieldN/APrice Target$51.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vericel alerts: Email Address Vericel MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1.9% Downside$51.33 Price TargetShort InterestHealthy5.60% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 15 Articles This WeekInsider TradingSelling Shares$3.10 M Sold Last QuarterProj. Earnings Growth354.55%From $0.11 to $0.50 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.19 out of 5 starsMedical Sector799th out of 936 stocksBiological Products, Except Diagnostic Industry136th out of 154 stocks 1.5 Analyst's Opinion Consensus RatingVericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVericel has only been the subject of 4 research reports in the past 90 days.Read more about Vericel's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.60% of the outstanding shares of Vericel have been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Vericel has recently decreased by 21.84%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VCEL. Previous Next 3.2 News and Social Media Coverage News SentimentVericel has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Vericel this week, compared to 4 articles on an average week.Search Interest4 people have searched for VCEL on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows1 people have added Vericel to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,101,269.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Vericel is held by insiders.Read more about Vericel's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vericel are expected to grow by 354.55% in the coming year, from $0.11 to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is -5,226.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is -5,226.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVericel has a P/B Ratio of 11.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vericel's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Vericel Stock (NASDAQ:VCEL)Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Read More VCEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCEL Stock News HeadlinesJuly 20, 2024 | insidertrades.comInsider Selling: Vericel Co. (NASDAQ:VCEL) CEO Sells 17,500 Shares of StockJuly 19, 2024 | insidertrades.comVericel Co. (NASDAQ:VCEL) Insider Sells $782,700.00 in StockJuly 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...July 17, 2024 | insidertrades.comInsider Selling: Vericel Co. (NASDAQ:VCEL) CFO Sells 5,000 Shares of StockJuly 10, 2024 | insidertrades.comVericel Co. (NASDAQ:VCEL) Insider Sells $24,525.00 in StockJune 26, 2024 | insidertrades.comSean C. Flynn Sells 1,474 Shares of Vericel Co. (NASDAQ:VCEL) StockJuly 25 at 6:08 AM | americanbankingnews.comStockNews.com Upgrades Vericel (NASDAQ:VCEL) to "Hold"July 22, 2024 | markets.businessinsider.comBuy Rating on Vericel: Expanding MACI’s Market Potential and Sustaining Top-Line GrowthJuly 26, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...July 22, 2024 | globenewswire.comVericel Announces Appointment of Karen Mahoney as Chief Human Resources OfficerJuly 21, 2024 | americanbankingnews.comDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) StockJuly 20, 2024 | americanbankingnews.comSean C. Flynn Sells 15,000 Shares of Vericel Co. (NASDAQ:VCEL) StockJuly 20, 2024 | americanbankingnews.comVericel Co. (NASDAQ:VCEL) Receives $51.33 Average Target Price from BrokeragesJuly 19, 2024 | americanbankingnews.comVericel (NASDAQ:VCEL) Reaches New 52-Week High on Analyst UpgradeJuly 18, 2024 | globenewswire.comVericel to Report Second-Quarter 2024 Financial Results on August 1, 2024July 18, 2024 | americanbankingnews.comVericel (NASDAQ:VCEL) Lowered to "Sell" at StockNews.comJuly 16, 2024 | americanbankingnews.comVericel (NASDAQ:VCEL) Price Target Increased to $57.00 by Analysts at Truist FinancialJuly 16, 2024 | americanbankingnews.comVericel (NASDAQ:VCEL) PT Lowered to $55.00 at BTIG ResearchSee More Headlines Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VCEL CUSIPN/A CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees314Year Founded1989Price Target and Rating Average Stock Price Target$51.33 High Stock Price Target$57.00 Low Stock Price Target$42.00 Potential Upside/Downside-1.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio473.36 P/E GrowthN/ANet Income$-3,180,000.00 Net Margins0.22% Pretax Margin0.61% Return on Equity0.21% Return on Assets0.13% Debt Debt-to-Equity RatioN/A Current Ratio5.20 Quick Ratio4.83 Sales & Book Value Annual Sales$197.52 million Price / Sales12.81 Cash Flow$0.02 per share Price / Cash Flow2,973.00 Book Value$4.73 per share Price / Book11.01Miscellaneous Outstanding Shares48,600,000Free Float46,075,000Market Cap$2.53 billion OptionableOptionable Beta1.70 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Dominick C. Colangelo Esq. (Age 60)CEO, President & Director Comp: $1.54MMr. Joseph Anthony Mara Jr. (Age 48)CFO & Treasurer Comp: $750.61kMr. Michael Halpin (Age 62)Chief Operating Officer Comp: $796.91kMr. Sean C. Flynn (Age 50)Chief Legal Officer Comp: $657.01kDr. Jonathan M. Hopper FRCSEd. (Age 62)M.B. Ch.B., Chief Medical Officer Comp: $672.16kMr. Jonathan D. SiegalPrincipal Accounting Officer, VP & Corporate ControllerMr. Eric BurnsVice President of Finance & Investor RelationsMr. Patrick J. FowlerSenior Vice President of Corporate Development & StrategyMr. Patrick HelfrichVice President of Marketing & Commercial StrategyMr. Mike GilliganSenior Vice President of SalesMore ExecutivesKey CompetitorsREGENXBIONASDAQ:RGNXAlectorNASDAQ:ALECiTeos TherapeuticsNASDAQ:ITOSC4 TherapeuticsNASDAQ:CCCCBlack Diamond TherapeuticsNASDAQ:BDTXView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 25,626 shares on 7/26/2024Ownership: 0.866%Bank of New York Mellon CorpBought 12,710 shares on 7/26/2024Ownership: 0.733%EFG Asset Management North America Corp.Bought 6,291 shares on 7/26/2024Ownership: 0.110%Legato Capital Management LLCBought 14,750 shares on 7/26/2024Ownership: 0.060%RiverPark Advisors LLCSold 344 shares on 7/26/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions VCEL Stock Analysis - Frequently Asked Questions How have VCEL shares performed this year? Vericel's stock was trading at $35.61 on January 1st, 2024. Since then, VCEL shares have increased by 46.9% and is now trading at $52.32. View the best growth stocks for 2024 here. How were Vericel's earnings last quarter? Vericel Co. (NASDAQ:VCEL) released its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. Vericel's revenue for the quarter was up 25.0% on a year-over-year basis. What is Nick Colangelo's approval rating as Vericel's CEO? 6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are Vericel's major shareholders? Top institutional shareholders of Vericel include Allspring Global Investments Holdings LLC (0.87%), Bank of New York Mellon Corp (0.73%), EFG Asset Management North America Corp. (0.11%) and Raymond James & Associates (0.10%). Insiders that own company stock include Dominick Colangelo, Robert L Md Zerbe, Joseph Anthony Mara Jr, Steven C Gilman, Jonathan Siegal, Michael Halpin, Sean C Flynn and Jonathan Mark Hopper. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX). This page (NASDAQ:VCEL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
